Highlights•CAR T cell clinical trial manufacturing data is investigated.•Three dominant
process routes are uncovered.•The trend in CAR T cell manufacturing is towards …

Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-
derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that …

CD19-specific chimeric antigen receptor (CAR19) T-cells effectively induce remission of B-
cell malignancy, but the cost and complexity of production using viral vectors is a factor …

Limited clinical benefit has been demonstrated for chimeric antigen receptor (CAR) therapy
of solid tumors, but coengineering strategies to generate so-called fourth-generation (4G) …

Purpose This phase I clinical trial is designed to assess the safety and feasibility of the
epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) T-cell generated …

Unprecedented efficacy of chimeric antigen receptor (CAR) T cell therapy in the treatment of
hematologic malignancies brings new hope for patients with many cancer types including …

The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies
to the market. To address the demands of the clinical and eventual commercial-scale …

Abstract In the United States the increasing number of Food and Drug Administration (FDA)-
approved, innovative, and potentially effective commercial cancer therapies pose a …

Cell therapy has proven to be a burgeoning field of investigation, evidenced by hundreds of
clinical trials being conducted worldwide across a variety of cell types and indications. Many …